Navigation Links
Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
Date:10/21/2008

or responses needed to proceed to Stage B. In Stage B, the trial is being expanded to include an additional 31 patients, for a total of 46 patients overall. Secondary objectives of the study include assessing time to tumor progression, duration of response, overall patient survival and safety parameters. Patients in the study are evaluated regularly for tumor response according to RECIST criteria.

The World Health Organization reports that breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that approximately 182,460 U.S. women will be diagnosed with breast cancer in 2008 and 40,480 women will die of the disease.

Bavituximab is a monoclonal antibody that binds to the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By binding to PS, bavituximab is believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels. Bavituximab currently is in two separate Phase II combination therapy trials for the treatment of advanced breast cancer and a Phase II combination therapy trial for the treatment of non-small cell lung cancer. A Phase I bavituximab monotherapy trial in advanced solid cancers is also continuing.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. ('/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... -- This report analyzes the worldwide markets ... the following Product Segments: Proteases, Polymerases, Carbohydrases, ... also analyzed are Pharmaceuticals & Diagnostics, Research/Biotechnology, ... separate comprehensive analytics for the US, Canada, ... America. Annual estimates and forecasts are provided ...
(Date:9/30/2014)... available in German . ... quantum dots in a semiconductor layer. Quantum dots are small ... processes. If a short laser pulse is fired at the ... dot experiences a change in the electromagnetic field around it. ... of light by the dot. As soon as the refractive ...
(Date:9/30/2014)... news release is available in German . ... the Technische Universitt Mnchen (TUM) have demonstrated a new ... experiments show that future computer chips could be based ... As the main enabling technology of the semiconductor industry ... limits, the TUM researchers and collaborators at the University ...
(Date:9/30/2014)... Sept. 30, 2014 Pacific Northwest Biotechnology, ... Summary Global Markets Direct,s, ,Pacific Northwest Biotechnology, ... an overview of the Pacific Northwest Biotechnology, LLC,s ... provides comprehensive information on the current therapeutic developmental ... comparative analysis at various stages, therapeutics assessment by ...
Breaking Biology Technology:Global Specialty Enzymes Industry 2Global Specialty Enzymes Industry 3Global Specialty Enzymes Industry 4Global Specialty Enzymes Industry 5Global Specialty Enzymes Industry 6Global Specialty Enzymes Industry 7Global Specialty Enzymes Industry 8Global Specialty Enzymes Industry 9Global Specialty Enzymes Industry 10Global Specialty Enzymes Industry 11Global Specialty Enzymes Industry 12Global Specialty Enzymes Industry 13Global Specialty Enzymes Industry 14Global Specialty Enzymes Industry 15Global Specialty Enzymes Industry 16Global Specialty Enzymes Industry 17Global Specialty Enzymes Industry 18Global Specialty Enzymes Industry 19Global Specialty Enzymes Industry 20Global Specialty Enzymes Industry 21Global Specialty Enzymes Industry 22Global Specialty Enzymes Industry 23Global Specialty Enzymes Industry 24Global Specialty Enzymes Industry 25Global Specialty Enzymes Industry 26Ultrafast remote switching of light emission 2A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3
... , , NEWARK, N.J., Aug. ... a specialty chemical technology based Life Science Company announced today ... an impartial blind testing protocol Ygiene(TM) Hospital Grade Antimicrobial was ... , Many of today,s commercially available antimicrobials and ...
... , SUNNYVALE, Calif., Aug. 5 Pharmacyclics, Inc. ... rights offering to purchase up to 22,500,000 shares of the Company,s common ... of 5:00 p.m., EDT, on July 31, 2009. The Company increased the ... 18,750,000 shares to up to 22,500,000 shares. , , ...
... CITY, Aug. 5 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... on endocrine therapy and oncology, will announce its second quarter ... August 11, 2009. The Company will host a conference call ... at 10:00 a.m., Eastern Time. , Participants may access the ...
Cached Biology Technology:BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing 2BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing 3Pharmacyclics, Inc. Rights Offering Oversubscribed 2Pharmacyclics, Inc. Rights Offering Oversubscribed 3
(Date:9/30/2014)... moorland burning is published today in the first authoritative ... relieving tensions on both sides of the grouse moor ... Burning on the Ecohydrology of River basins) project has ... predominantly to support red grouse populations for gun sports, ... and physical properties, river water chemistry and river ecology. ...
(Date:9/30/2014)... comprehensive assessment conducted by the Ocean Health Index ... 100 in overall health. In addition, for the ... the 15 ocean regions beyond national jurisdiction (high-seas ... healthy climate, safeguarding biodiversity and providing sustainable food ... the index, a partnership led by scientists from ...
(Date:9/30/2014)... National Institutes of Health (NIH) awarded Lawrence Livermore ... an electrode array system that will enable researchers ... unprecedented resolution and scale. , LLNL,s grant-funded project ... Obama,s BRAIN (Brain Research through Advancing Innovative ... revolutionize our understanding of the human mind and ...
Breaking Biology News(10 mins):Grouse moor burning causes widespread environmental changes 2Rating the planet's oceans 2Rating the planet's oceans 3NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3
... Springer is launching the Journal of Environmental ... the Association for Environmental Studies and Sciences (AESS). ... in print and on Springer,s online platform www.springerlink.com ... Sciences provides a peer-reviewed, academically rigorous and professionally ...
... This release is available in Spanish . ... was a significant step in knowing the causes of cancer better, ... protein in the cells known as SIRT3, induces the proliferation of ... a therapeutic target in the development of effective therapies for cancer. ...
... Access to Research Careers) Program has announced the travel ... of The American Association of Immunologists (AAI) to be ... These awards are meant to promote the entry ... mainstream of the basic science community and to encourage ...
Cached Biology News:Discovery of protein that alters nutrition of breast cancer cells 2Discovery of protein that alters nutrition of breast cancer cells 3MARC travel awards announced for Immunology 2011 2MARC travel awards announced for Immunology 2011 3
Request Info...
Polyclonal Antibody to SHPRH...
Polyclonal Antibody to Coronin / CORO1C This antibody was developed against synthetic peptides corresponding to amino acids 407-420 of human CORO1C....
Mouse Wnt-9b Biotinylated Affinity Purified PAb ENTREZ GeneID: 22412...
Biology Products: